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The aim of this meta-analysis was to compare the efﬁcacy of metronidazole and van-
comycin  for the treatment of Clostridium difﬁcile infection, especially to investigate which
agent was superior for treating either mild or severe C. difﬁcile infection. A meta-analysis
of  randomized controlled trials and cohort studies identiﬁed in Pubmed, Embase, and the
Cochrane Library was conducted. Four randomized controlled trials and two cohort stud-
ies  involving 1218 patients were included in this meta-analysis. Metronidazole was inferior
to  vancomycin for treating C. difﬁcile infection in terms of both initial clinical cure rates
(risk  ratio, RR = 0.91, 95% conﬁdence interval, CI = 0.84–0.98, p = 0.02) and sustained cure rates
(RR  = 0.88, 95% CI = 0.82–0.96, p = 0.003). For mild C. difﬁcile infection, the efﬁcacy of metroni-
dazole and vancomycin resulted in similar clinical cure rates (RR = 0.94, 95% CI = 0.84–1.04,
p  = 0.21) and sustained cure rates (RR = 0.93, 95% CI = 0.83–1.05, p = 0.26). For severe C. difﬁ-
cile  infection the efﬁcacy of vancomycin was superior to metronidazole in terms of clinical
cure  rates (RR = 0.81, 95% CI = 0.69–0.95, p = 0.009), whereas sustained cure rates were similar
(RR  = 0.86, 95% CI = 0.72–1.02, p = 0.08). Regarding microbiological cure metronidazole therapy
was as effective as vancomycin therapy (RR = 0.88, 95% CI = 0.64–1.21, p = 0.43). Recurrence
rates  with metronidazole and vancomycin for both mild C. difﬁcile infection (RR = 0.95, 95%
CI  = 0.56–1.60, p = 0.85) and severe C. difﬁcile infection (RR = 1.27, 95% CI = 0.85–1.91, p = 0.25)
were not different. Likewise, no difference in all-cause mortality was found as well (RR = 0.87,
95% CI = 0.56–1.35, p = 0.53). In conclusion, vancomycin provides improved initial clinical and
sustained cure rates in patients with C. difﬁcile infection compared with metronidazole, espe-h sevcially  in patients witconsidered ﬁrst line thera
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Introduction
Clostridium difﬁcile infection (CDI) is prevalent in the health-
care setting throughout the developed world1 and may result
in serious complications, longer hospital stay, and additional
medical costs.2 There was a marked increase in incidence and
mortality rate of CDI in Europe, Canada, and United States
during in the past 15 years. The increase was attributable
mainly to the emergence of a new, hypervirulent strain of
BI/NAP1/027, which emerged in 2003 in North America and
2005 in Europe, respectively. The data from 28 community hos-
pitals in the southern United States suggested that C. difﬁcile
had replaced methicillin-resistant Staphylococcus aureus as the
most common etiology of healthcare-associated infections.3
Metronidazole and vancomycin are the most commonly used
antibiotics for CDI, which historically were thought to be sim-
ilar in efﬁcacy.4,5 In 1995, the Centers for Disease Control and
Prevention of the United States recommended reducing the
use of vancomycin in hospitals because it might contribute
to increasing the prevalence of vancomycin-resistant Entero-
coccus (VRE).6 Since then metronidazole had been commonly
used as ﬁrst-line treatment for CDI. With the emergence and
prevalence of hypervirulent strain of C. difﬁcile (BI/NAP1/027),
the infections have become more  severe and comparison
of metronidazole and vancomycin was reassessed,7,8 espe-
cially when used to treat patients with severe CDI. Zar et al.
conducted the ﬁrst prospective, randomized, double-blind,
placebo-controlled, single-center trial comparing metroni-
dazole and vancomycin for CDI. The results showed that
metronidazole and vancomycin were equally effective, but
vancomycin was superior for severe CDI patients.9 Their
ﬁndings were of tremendous signiﬁcance and made sugges-
tions to update clinical practice guidelines. The guidance
recommended that metronidazole was to be used for mild
to moderate CDI and vancomycin for severe CDI, which was
determined by the severity of symptoms.10–13 However, in a
study by Zar et al., 22 participants were excluded from the
analysis and by strict ITT analysis of all 82 randomly assigned
patients with severe disease the initial cure rate was not sig-
niﬁcantly different between vancomycin and metronidazole
(79% vs. 66%, p = 0.22).3,14 Next, Le et al. reported higher clini-
cal response rate in severe disease patients with vancomycin,
but only a minority of patients had received vancomycin
(n = 8).15 Recently, Johnson et al. reported similar rates of clini-
cal success in patients with severe CDI in patients treated with
vancomycin or metronidazole, but metronidazole was inferior
to vancomycin for all the CDI patients.16 In addition, Pepin
et al. suggested that loss of superiority of vancomycin over
metronidazole coincided with the emergence of NAP1/027.17
Therefore, we  conducted a meta-analysis stratifying patients
according to disease severity, to investigate the efﬁcacy of met-
ronidazole compared to vancomycin, and to investigate which
agent was superior for treating either mild or severe disease.
Materials  and  methodsData  sources
A systematic search of literature in MEDLINE via Pubmed
(1978 to Oct 31, 2014), Embase (1978 to Oct 31, 2014) and 1 5;1  9(4):339–349
the Cochrane Central Register of Controlled Trials (Cochrane
library) was conducted to identify the relevant studies. The
key search terms were “metronidazole and vancomycin and
clostridium difﬁcile”; “metronidazole and vancomycin and pseu-
domembrannous colitis”; “metronidazole and vancomycin
and antibiotic associated diarrhea”. All references of the ini-
tially identiﬁed articles, including the relevant review papers,
were hand searched and reviewed. Abstracts presented in
scientiﬁc conferences that were unavailable to us were not
searched for.
Study  selection
Two reviewers (X.ZH.D and N.B.) independently searched
articles and examined the relevant studies for further assess-
ment. A study was considered eligible if it was an RCT or
prospective cohort study, if it involved adult patients with
CDI including mild and/or severe disease; if it studied safety
or efﬁcacy of metronidazole and vancomycin; if it reported
speciﬁc data regarding clinical and microbiological cure, mor-
tality, and adverse events. Blinded or unblinded studies and
randomized or nonrandomized designs were all included.
Experimental studies based on pharmacokinetic or pharma-
codynamic variables were excluded. Clinical trials involving
drug combination therapy were also excluded.
Qualitative  assessment
Evaluation of the methodological quality of the RCTs and
cohort studies included in the meta-analysis were performed
independently by two reviewers (X.ZH.D and N.B.) according
to the checklist developed by Downs and Black.18 This tool
assessed both randomized and nonrandomized studies pro-
viding for both an overall score of study quality and a proﬁle of
scores for assessing the quality of reporting, external validity,
internal validity (bias, confounding), and power. High-quality
studies scored 15 or more  points, whereas low-quality studies
scored 14 or fewer points.
Data  extraction
Two reviewers independently extracted data from each study
with predesigned review form. In case of any disagreement
between the two reviewers, a third reviewer extracted the data
until reaching consensus. The data extracted from each study
were: (i) year of publication; (ii) patient population; (iii) num-
ber of patients; (iv) antimicrobial agents and dosages used; (v)
clinical and microbiological outcomes; and (vi) all-cause mor-
tality. We used ITT analysis, deﬁned as including all randomly
assigned patients.
Analyzed  outcomes
Initial clinical cure, sustained cure, microbiological cure,
recurrence, and all-cause mortality were used as outcome
measures for this meta-analysis. We  used the deﬁnition of
initial clinical cure and recurrence reported in the individual
studies and recorded between-study differences. Outcomes
were also analyzed based on the following populations: (i)
all patients including mild and severe CDI; (ii) patients with
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ild CDI; (iii) patients with severe CDI; and (iv) patients with
seudomembranous colitis (PMC).
ata  analysis  and  statistical  methods
tatistical analyses were done with Review Manager program,
ersion 5.2 (Cochrane Collaboration). Heterogeneity between
tudies was assessed by 2 test of heterogeneity (p < 0.05 was
eﬁned to indicate signiﬁcant heterogeneity) and I2 measure
f inconsistency. Pooled risk ratios (RRs) and 95% conﬁdence
ntervals (CIs) for outcomes were calculated by the ﬁxed-
ffect model (FEM) if there was no statistically signiﬁcant
eterogeneity among the included studies. Otherwise, the
andom-effect model (REM) would be used. Subgroup analyses
ere performed based on the severity of disease.
esults
elected  clinical  studieshe ﬂow diagram (Fig. 1) shows the detailed screening and
election process for the studies included in this meta-
nalysis. The literature search identiﬁed 2945 abstracts. We
702 duplicates removed 
3647 records identified through database searching 
2945 records after duplicates removed 
2898 records excluded from
titles and abstracts   
47 full-text articles assessed for eligibility 
41 articles excluded due to: 
3 duplicates of published trials 
5 review
22 study design 
4 without control group 
1 pharmacokinetic study
4 case series 
2 letters 
6 studies included in meta-analysis 
Fig. 1 – Flow diagram of included studies.5;1 9(4):339–349 341
obtained 47 full papers for detailed evaluation. Of the 41
excluded studies, three articles were excluded because they
were parts of RCTs already included in this meta-analysis,
one trial was excluded because it was a pharmacokinetic
study,19 other studies were excluded because of different
study designs such as lack control regimen, combination
with other antibiotics,20,21 different outcomes,22 or differ-
ent type of patients,23 etc. Thus, six studies were ultimately
included in this meta-analysis: two cohort studies15,24 and
four RCTs.4,5,9,16
Study  characteristics
The main characteristics of the analyzed studies are shown
in Table 1. The included studies were of high quality (two
RCTs had a score of 23, two a score of 20, and two cohort
studies a score of 17). Two RCTs were conducted by using
randomized, double-blind and placebo-control designs,9,16
while the other two by using randomization only.4,5 Three
studies were conducted in the United States,4,9,15 two stud-
ies were conducted in Austria,5,24 whereas a single study
including two RCTs conducted in the United States and
Europe, respectively.16 The deﬁnition of CDI, initial clinical
cure, and recurrence are shown in supplementary Table 1.
The deﬁnition of CDI invariably included a test for C. difﬁcile
toxin, microorganisms or PMC  combined with diarrhea. How-
ever, deﬁnitions of diarrhea slightly varied, but most studies
referred to diarrhea as unformed stools at least three times
over a period of 24 h.5,9,15,16 The outcomes of initial clinical
cure and recurrence were reported in all studies with def-
initions slightly different. For example, ﬁve studies4,5,9,15,16
considered initial clinical cure if diarrhea resolved within
6–8 treatment days, whereas Zar9 and Wenisch5 incorporate
a negative result of a C. difﬁcile toxin or C-reactive protein
measurement. Most considered recurrence when symptoms
reappeared and/or microbiological positive test results were
conﬁrmed during follow-up of 21–30 days after initial reso-
lution of symptoms.4,5,9,15,16 Sustained cure was deﬁned as
clinical cure in the absence of any recurrence during follow-up,
which was calculated as initial clinical cure minus  recurren-
ces. The recovery reported by Wenisch24 was considered as
sustained cure. Patients with moderate CDI in the study by
Johnson et al. were considered as severe disease, while all
patients included in the study by Wenisch et al. were consid-
ered as mild disease based on CDI severity assessment used in
the studies by Zar9 and guidelines.11 In addition, Wenisch et al.
did not indicate the treatment allocation of seven dropouts
from all of groups,5 Johnson et al. reported that analysis
included all randomized patients who received at least one
dose of antibiotics and had any post-dose evaluation,16 which
might have inﬂuenced the ITT results.
Supplementary table related to this article can be
found, in the online version, at http://dx.doi.org/10.1016/
j.bjid.2015.03.006.
Initial  clinical  cureThe initial clinical cure of the metronidazole group was
numerically lower than that of the vancomycin group and a
statistically signiﬁcant difference was found (1013 patients,
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Metronidazole Vancomycin
Study or subgroup Events Total TotalEvents Weight
Risk ratio
M-H, Random,95% CI M-H, Random,95% CI
Risk ratio
0.5 0.7 1 1.5 2
Favours [vancomycin]       Favours [metronidazole]
Johnson 2014 202
101
39
29
66Zar 2007
Wenisch 1996
Teasley 1983
Le 2012
278
128
43
31
90 69
29
51
16
210 258
16
56
31
82
 25.8%
20.3%
19.6%
18.9%
15.4%
0.89 [0.81,0.98]
0.81 [0.72,0.92]
1.00 [0.88,1.13]
1.00 [0.88,1.14]
0.87 [0.75,1.02]
0.91 [0.84,0.98]100.0%443570
437 375
Total (95% CI)
Total events
Heterogeneity: Tau2=0.00; Chi2=7.93, df=4 (P = 0.09); l2=50%
Test for overall effect: Z=2.37 (P = 0.02)
Metronidazole Vancomycin Risk ratio
M-H, Fixed,95% CI
Risk ratio
M-H, Fixed,95% CIStudy or subgroup Events Total TotalEvents Weight
Johnson 2014
Zar 2007
Le 2012
37
69
59 75
77
46 39
 8
62 75
 8
44 34.0%
13.0%
52.9% 0.95 [0.81, 1.11]
0.94 [0.79, 1.13]
0.91 [0.76, 1.08]
0.5 0.7 1 1.5 2
Favours [Vancomycin]       Favours [Metronidazole]
Total (95% CI)
Total events
Heterogeneity: Chi2=0.17, df=2 (P = 0.92); l2=0%
Test for overall effect: Z=1.24 (P=0.21)
198
165 109
127 100.0% 0.94 [0.84,1.04]
Johnson 2014 143
Zar 2007
Le 2012 32
29
204 186
203
51
44
298
148
8
30
183
8
38
229
25.7%
13.9%
13.6%
53.3%
Total events
Heterogeneity: Tau2=0.01; Chi2=3.67, df=2 (P=0.16); l2=45%
Test for overall effect: Z=2.62 (P=0.009)
Subtotal (95% CI)
1.3.1 severe CDI
Metronidazole Vancomycin Risk ratio
M-H, Random,95% CI
Risk ratio
Study or subgroup Events Total TotalEvents Weight M-H, Random,95% CI
0.87 [0.78, 0.98]
0.66 [0.51, 0.86]
0.83 [0.64, 1.09]
0.81 [0.69, 0.95]
1.00 [0.89, 1.13]
1.01 [0.86, 1.18]
1.00 [0.91, 1.10]
25.0%
21.7%
46.7%
20
17
37
20
16
36
32
13
19
13
18
31
1.3.2 PMC
Teasley 1983
Wenisch 1996
Total events
Subtotal (95% CI)
Heterogeneity: Tau2=0.00; Chi2=0.00, df=1 (P=0.95); l2=0%
Test for overall effect: Z=0.05 (P=0.096)
Test for overall effect: Z=1.74 (P=0.08)
Heterogeneity: Tau2=0.01; Chi2=12.37, df=4 (P=0.01); l2=68%
Total events
Total (95% CI)
Test for subgroup differences: Chi2=5.17, df=1 (P=0.02); l2=80.6%
235 222
330 266 100.0% 0.89 [0.78, 1.02]
0.5 0.7 1 1.5 2
Favours [Vancomycin]       Favours [Metronidazole]
a
b
c
Fig. 2 – Meta-analysis of initial clinical cure rates comparing metronidazole to vancomycin for all CDI, mild CDI, severe CDI
and PMC.
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Johnson 2014-301
Wenisch 1996
Teasley 1983
Le 2012
Subtotal (95% CI)
Total events
Heterogeneity: Chi2=5.39, df=3 (P=0.15); l2=44%
Test for overall effect: Z=2.95 (P=0.003)
Zar 2007
Total events
0.5 0.7 1 1.5 2
Favours [vancomycin] Favours [metronidazole]
0.5 0.7 1 1.5 2
Favours [vancomycin]       Favours [metronidazole]
103
101
39
66
309
143
128
43
90
404
245
69
51
16
109 134
16
56
82
288 65.9%
18.4%
11.3%
7.4%
28.7%
26.7%
7.4%
34.1%156
31
125101
29
130128
135
31
166
99
29
0.89 [0.83,0.96]
0.87 [0.75,1.02]
1.00 [0.88,1.13]
0.81 [0.72,0.92]
0.89 [0.78,1.01]
0.91 [0.79,1.04]
1.00 [0.88,1.14]
0.93 [0.83,1.03]
3.1.2 Europe
Johnson 2014-302
Subtotal (95% CI)
Heterogeneity: Chi2=1.37, df=1 (P=0.24); l2=27%
Test for overall effect: Z=1.38 (P=0.17)
Total events
Total (95% CI)
Heterogeneity: Chi2=7.92, df=5 (P=0.16); l2=37%
Test for overall effect: Z=3.19 (P=0.001)
100.0%444570
437 375
0.90 [0.85,0.96]
Metronidazole Vancomycin
Study or subgroup Events Total TotalEvents Weight
Risk ratio
M-H, Fixed,95% CI M-H, Fixed,95% CI
Risk ratioa
3.1.1 the United States
16.1%
0.83 [0.67,1.01]
0.82 [0.63,1.07]
1.07 [0.90,1.28]
0.81 [0.67,0.99]
0.88 [0.76,1.03]
0.88 [0.73,1.06]
1.00 [0.76,1.31]
0.92 [0.78,1.10]
0.92 [0.82,1.03]
8.7%
18.9%
43.7%198
42
31
12583
24
34
141
329
163
31
13579
24
122
225
0.91 [0.83,0.98]100.0%486733
347478
14.0%
18.0%
15.4%
56.3%
8.9%16
56
82
134
288
64
45
13
84
206
90
43
128
14374
85
37
57
253
Le 2012
Zar 2007
Teasley 1983
Johnson 2014-301
3.2.1 the United States
Subtotal (95% CI)
Total events
Metronidazole Vancomycin
Study or subgroup Events Total TotalEvents Weight
Risk ratio
M-H, Random,95% CI
Risk ratio
M-H, Random,95% CI
Johnson 2014-302
Total events
3.2.2 Europe
Wenisch 1996
Wenisch 2012
Subtotal (95% CI)
Total (95% CI)
Total events
Test for overall effect: Z=2.35 (P=0.02)
Test for overall effect: Z=1.40 (P=0.16)
Test for overall effect: Z=1.60 (P=0.11)
b
Heterogeneity: Tau2=0.01; Chi2=6.40, df=3 (P=0.09); l2=53%
404
Heterogeneity: Tau2=0.00; Chi2=0.60, df=2 (P=0.74); l2=0%
Heterogeneity: Tau2=0.00; Chi2=7.04, df=6 (P=0.32); l2=15%
Test for subgroup differences: Chi2=0.18, df=1 (P=0.67), l2=0%
Test for subgroup differences: Chi2=0.34, df=1 (P=0.56), l2=0%
Fig. 3 – Meta-analysis of initial clinical cure and sustained cure rates comparing metronidazole to vancomycin for all the
CDI patients from the United States and Europe.
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Table 1 – characteristics of 6 identiﬁed prospective studies.
Study Design of
study
Country Duration
of study
Drug regimen Duration
of
treatment
Duration
of follow
up
Intention
to  treat
Study
quality
score
Metronidazole Vancomycin
Teasley
et al.
(1983)4
RCT United
State
1982.1–1983.1  250 mg, q.i.d,
p.o
500 mg, q.i.d,
p.o
10 days 21 days 43 vs. 56 20
Wenisch
et al.
(1996)5
RCT Austria/Europe 1993.1–1995.4 500 mg, t.i.d,
p.o
500 mg, t.i.d,
p.o
10 days 30 days 31 vs. 31 20
Zar et al.
(2007)9
RCT United
State
1994.10–2002.6  250 mg, q.i.d,
p.o
125 mg, q.i.d,
p.o
10 days 21 days 90 vs. 82 23
Le et al.
(2012)15
CS United
State
2006–2008  500 mg, q6h
p.o or iv
125 mg, q.i.d,
p.o
NA 21 days 128 vs. 16 17
Wenisch
et al.
(2012)24
CS Austria/Europe 2008.12–2010.3 500 mg, t.i.d
p.o or iv
250 mg, q.i.d,
p.o
10 days 30 days 163 vs. 42 17
Johnson
et al.
(2014)16
RCT United
State,
Canada;
Europe
2005–2007  375 mg, q6h,
p.o
125 mg, q6h,
p.o
10 days 28 days 278 vs.
258
23RCT, randomized controlled trial; CS, cohort study; NA, not available.
REM, 0.91, 95% CI = 0.84–0.98, p = 0.02, Fig. 2a). Cure was
achieved in 85% of patients receiving vancomycin compared
to 77% of patients receiving metronidazole. The results of
meta-analysis according to patient subgroup are shown in
Fig. 2b and c. No signiﬁcant difference was found between
vancomycin and metronidazole for the patients with mild
CDI (325 patients, FEM, RR = 0.94, 95% CI = 0.84–1.04, p = 0.21,
Fig. 2b) and for PMC patients (69 patients, REM, RR = 1.00,
95% CI = 0.91–1.10, p = 0.96, Fig. 2c) in initial clinical cure rates.
The initial clinical cure rates were signiﬁcantly higher with
vancomycin (81%) versus metronidazole (68%) in those with
severe CDI (527 patients, REM, RR = 0.81, 95% CI = 0.69–0.95,
p = 0.009, Fig. 2c). However, when the patients with PMC in
two studies4,5 were considered as severe CDI, no signiﬁ-
cant difference was found (596 patients, FEM, RR = 0.89, 95%
CI = 0.78–1.02, p = 0.08, Fig. 2c). The pooled analysis of stud-
ies conducted in the United States showed that the efﬁcacy
of vancomycin was superior to metronidazole (692 patients,
FEM, RR = 0.89, 95% CI = 0.83–0.96, p = 0.003, Fig. 3a).
Sustained  cure
The sustained cure in the metronidazole group was numeri-
cally lower than that of the vancomycin group (1218 patients,
FEM, 0.88, 95% CI = 0.82–0.96, p = 0.003, Fig. 4a). Sustained cure
rates were 72% and 65%, for metronidazole and vancomycin,
respectively. No signiﬁcant difference was found between
vancomycin and metronidazole for the patients with mild
CDI (530 patients, FEM, RR = 0.93, 95% CI = 0.83–1.05, p = 0.26,
Fig. 4b), with severe CDI (527 patients, REM, RR = 0.86, 95%
CI = 0.72–1.02, p = 0.08, Fig. 4c) and with PMC  (69 patients, REM,
RR = 1.07, 95% CI = 0.88–1.29, p = 0.51, Fig. 4c). No signiﬁcant dif-
ference was found between vancomycin and metronidazole
for all CDI patients from the United States (692 patients, REM,
RR = 0.88, 95% CI = 0.76–1.03, p = 0.11, Fig. 3b) and Europe (527
patients, REM, RR = 0.92, 95% CI = 0.82–1.03, p = 0.16, Fig. 3b).Recurrence  rate
There was no statistically signiﬁcant difference in recurrence
rates between metronidazole and vancomycin (812 patients,
FEM, RR = 1.13, 95% CI = 0.84–1.54, p = 0.42, Fig. 5a). Recurrence
rates were 18% with metronidazole and 16% with vancomycin.
No signiﬁcant difference between vancomycin and metroni-
dazole for mild CDI patients (274 patients, FEM, RR = 0.95, 95%
CI = 0.56–1.60, p = 0.85, Fig. 5b), for severe CDI patients (399
patients, FEM, RR = 1.27, 95% CI = 0.85–1.91, p = 0.25, Fig. 5c), and
for PMC (67 patients, FEM, RR = 0.64, 95% CI = 0.13–3.19, p = 0.59,
Fig. 5c).
Microbiological  cure
Two relevant RCTs provided microbiological cure rates,
deﬁned as negative results of post-treatment follow-up stool
culture and cytotoxin assay for C. difﬁcile in clinical symp-
tomless treated patients.4,5 Regarding microbiological cure,
metronidazole therapy was as effective as vancomycin ther-
apy (161 patients, FEM, RR = 0.88, 95% CI = 0.64–1.21, p = 0.43,
Fig. 6).
All-cause  death  rate
Five relevant studies provided the all-cause death
rate.4,9,15,16,24 There was no statistically signiﬁcant differ-
ence between patients treated with metronidazole and those
treated with vancomycin (1166 patients, FEM, RR = 0.87, 95%
CI = 0.56–1.35, p = 0.53, Fig. 7). All-cause death rates were 9.5%
and 7.6% for metronidazole and vancomycin, respectively.Discussion
CDI is a serious problem in the health care system
with an increasing incidence worldwide which can cause
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Metronidazole Vancomycin
Study or subgroup Events Total TotalEvents Weight
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Fig. 4 – Meta-analysis of sustained cure rate comparing metronidazole to vancomycin for all CDI, mild CDI, severe CDI, and
PMC.
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igniﬁcant morbidity and mortality.25 Mortality rates reported
or patients with severe CDI range from 9% to 25%; more  than
ne-half of these deaths are related to CDI.14,26 It is especially
mportant to treat patients with severe CDI by using appropri-
te antimicrobial therapy.
In this meta-analysis we found that vancomycin was supe-
ior to metronidazole in terms of initial clinical cure and
ustained cure in CDI patients. Microbiological cure rates, was
umerically lower with metronidazole therapy than with van-
omycin, although the difference was not signiﬁcant. Authors
f a 2011 position paper in their pooled analysis found equiv-
lent rates of initial clinical cure with metronidazole and
ancomycin, the most commonly used agents.27,28 This incon-
istency was mainly because of the different included studies
n each systematic reviews. We included three more  studies
n the current meta-analysis.15,16,24 When data were analyzed
ccording to the severity of CDI, treatment with vancomycin
r metronidazole did not differ for patients with mild dis-
ase. However, the clinical cure and sustained cure rates
ith vancomycin in patients with severe CDI was signiﬁ-
antly greater than those rates in the metronidazole group.
e found insufﬁcient evidence that vancomycin and met-onidazole were equally effective in patients with PMC, due
o the small number of patients assessed. PMC has been
sed as a marker of severe disease.12 When severe CDIparing metronidazole to vancomycin for CDI.
patients included PMC patients, no signiﬁcant difference
was found between metronidazole and vancomycin therapy.
Though no statistical difference was observed, a strong ten-
dency toward higher initial clinical cure and sustained cure
rates was noted in the vancomycin group, whereas it was
the same for patients with mild CDI. Thus, for severe CDI
patients vancomycin was superior to metronidazole. Venu-
gopal et al. demonstrated that patients with severe CDI  were
more prone to switch to vancomycin, suggesting that these
patients were responding poorly to metronidazole.29 These
results were conﬁrmed in the current meta-analysis. Treat-
ment outcomes with metronidazole was poor because blood
ﬂow to the colon in patients with severe disease could have
decreased resulting in less transudation of metronidazole
into the lumen.30,31 In addition, ﬁdaxomicin was recently
approved for treatment of CDI and can be used as a secondary
agent in case of failure with vancomycin or metronidazole
because ﬁdaxomicin remained detectable in stool samples col-
lected up to ﬁve days after a single dose.32 In a meta-analysis
study, ﬁdaxomicin demonstrated similar clinical cure rates
to vancomycin with signiﬁcant decrease in the recurrence
rate in both severe and non-severe CDI patients.33 There-
fore, for initial treatment of severe CDI, oral vancomycin
is the ﬁrst-line drug; alternatively, oral ﬁdaxomicin can be
used.
i s . 2 0
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1
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results from two multinational, randomized, controlled trials.
Clin Infect Dis. 2014;59:345–54.348  b r a z j i n f e c t d 
The recurrence rates of vancomycin and metronidazole
were in general agreement with previous data and no sig-
niﬁcant difference was found.27,28 However, vancomycin was
associated with lower recurrence rates than metronidazole in
both all CDI patients and those with severe CDI. Our study sug-
gests that all-cause death rate was not signiﬁcantly different
between vancomycin and metronidazole in all CDI patients.
All-cause mortality rate from all CDI patients was 100/1166
(8.5%), which is lower than a European survey showing a mor-
tality rate for all cases of 101/455 (22%) after three months.1
The ﬁndings of the present meta-analysis must be viewed
in the context of potential limitations. First, the epidemiology
of C. difﬁcile has changed rapidly with a large proportion of
severe and recurrent cases occurring in these countries than
previously reported.1 This might result in differences of study
populations. Second, new methods for CDI diagnosis have
emerged during the past decade. The use of more  sensitive
and rapid tests for CDI diagnosis is critical for the clinical man-
agement of patients. Although diagnostic criteria were not as
stringent in some cases, response to treatment did not differ
substantially within a single drug regimen or between drugs.4
Third, as this meta-analysis have included a relatively small
number of studies, especially RCTs, the precision of the esti-
mates might have been compromised. Fourth, investigators
were not blinded to treatment allocation in the four studies,
which may have introduced bias to the reported outcomes of
effectiveness. Fifth, most included studies didn’t make sure
that all cases of diarrhea of the included patients was caused
by C. difﬁcile,  because these did not exclude the presence of
other pathogens in the stools as the cause of diarrhea.4,5 Sixth,
the severity score is still not validated and scientiﬁc enough,
and needed to improve not only for the standardization of
future studies, but also for use in clinical practice.27,34 There-
fore, the current results need to be further conﬁrmed.
In conclusion, despite the limitations of the current meta-
analysis, these analyses indicate that vancomycin offers
signiﬁcant beneﬁts in the treatment of CDI compared to met-
ronidazole. Patients tolerated the two drugs well and relapse
rates were similar. For patients with mild CDI, metronidazole
therapy was as clinically effective as vancomycin; for patients
with severe CDI vancomycin was more  effective than metro-
nidazole. This difference in efﬁcacy was most evident in the
subgroup of severe CDI and supported the recent recommen-
dations to using vancomycin as ﬁrst-line therapy for severe
CDI.
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